Mielenz, D
,
Reichel, M http://orcid.org/0000-0001-7886-2784
Jia, T http://orcid.org/0000-0001-5399-2953
Quinlan, E B
Stöckl, T
Mettang, M
Zilske, D
Kirmizi-Alsan, E
Schönberger, P
Praetner, M
Huber, S E
Amato, D
Schwarz, M
Purohit, P
Brachs, S
Spranger, J http://orcid.org/0000-0002-8900-4467
Hess, A
Büttner, C
Ekici, A B
Perez-Branguli, F
Winner, B
Rauschenberger, V
Banaschewski, T
Bokde, A L W
Büchel, C
Conrod, P J
Desrivières, S
Flor, H
Frouin, V http://orcid.org/0000-0001-9360-6623
Gallinat, J
Garavan, H
Gowland, P
Heinz, A
Martinot, J-L
Lemaitre, H
Nees, F
Paus, T
Smolka, M N
Schambony, A
Bäuerle, T
Eulenburg, V http://orcid.org/0000-0002-4878-5746
Alzheimer, C
Lourdusamy, A
Schumann, G
Müller, C P
Article History
Received: 7 October 2016
Revised: 3 February 2017
Accepted: 10 February 2017
First Online: 11 April 2017
Competing interests
: TB has served as an advisor or consultant to Bristol-Myers Squibb, Desitin Arzneimittel, Eli Lilly, Medice, Novartis, Pfizer, Shire, UCB and Vifor Pharma; he has received conference attendance support, conference support or speaking fees from Eli Lilly, Janssen McNeil, Medice, Novartis, Shire and UCB; and he is involved in clinical trials conducted by Eli Lilly, Novartis and Shire; the present work is unrelated to these relationships. JG has received research funding from the German Federal Ministry of Education and Research, AstraZeneca, Eli Lilly, Janssen-Cilag and Bristol-Myers Squibb; he has received speaking fees from AstraZeneca, Janssen-Cilag and Bristol-Myers Squibb. The remaining authors declare no conflict of interests.